NASDAQ: QTI

QT IMAGING HOLDINGS, INC.

CIK 0001844505 · SIC 3845 · Electromedical Equipment

Micro Revenue $19M Assets $31M as of Nov 15, 2026

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (CNXC 10-Q) is open in full — no account needed.

8-K Filed Nov 12, 2026 · Period ending Nov 11, 2026

Summary not yet generated.

8-K Filed Nov 10, 2026 · Period ending Nov 10, 2026

Summary not yet generated.

Partner

Trade QTI commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

10-Q Filed Nov 10, 2026 · Period ending Sep 30, 2026

Summary not yet generated.

8-K Filed Aug 31, 2026 · Period ending Aug 28, 2026

Summary not yet generated.

8-K Filed Aug 18, 2026 · Period ending Aug 18, 2026

Summary not yet generated.

10-Q Filed Aug 12, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

8-K Filed Aug 12, 2026 · Period ending Aug 12, 2026

Summary not yet generated.

8-K Filed Jul 28, 2026 · Period ending Jul 28, 2026

Summary not yet generated.

8-K Filed May 21, 2026 · Period ending May 15, 2026

Summary not yet generated.

424B5 Filed May 15, 2026 Red flag

QT Imaging prices $10M offering of 1.2M shares and pre-funded warrants at $5.00 per share

5 material changes detected. Sign up free to read the summary.

10-Q Filed May 13, 2026 · Period ending Mar 31, 2026

Summary not yet generated.

10-K Filed Mar 25, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

424B3 Filed Jan 29, 2026

Summary not yet generated.

424B3 Filed Dec 31, 2025

Summary not yet generated.

S-1/A Filed Dec 29, 2025

Summary not yet generated.

S-1 Filed Nov 3, 2025

Summary not yet generated.

10-K Filed Mar 31, 2025 · Period ending Dec 31, 2024

Summary not yet generated.

424B3 Filed Mar 3, 2025

Summary not yet generated.

S-1/A Filed Jan 31, 2025

Summary not yet generated.

S-1 Filed Jan 16, 2025

Summary not yet generated.

S-1/A Filed May 20, 2024

Summary not yet generated.

S-1 Filed Apr 2, 2024

Summary not yet generated.

10-K/A Filed Jun 15, 2023 · Period ending Dec 31, 2022

Summary not yet generated.

10-Q/A Filed Jun 15, 2023 · Period ending Mar 31, 2023

Summary not yet generated.

Latest financial statements

From 10-Q filed Nov 10, 2026 (period ending Sep 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

(In thousands, except per share data)

Description Three months ended September 30, 2026 Three months ended September 30, 2025 Nine months ended September 30, 2026 Nine months ended September 30, 2025
Revenue 7,340 4,192 21,305 10,650
Cost of revenue 4,311 2,389 12,544 5,208
Gross profit 3,029 1,803 8,761 5,442
Operating expenses:
Research and development 1,724 939 5,072 2,692
Selling, general and administrative 3,753 2,516 10,350 6,487
Total operating expenses 5,477 3,455 15,422 9,179
Loss from operations (2,448) (1,652) (6,661) (3,737)
Non-operating income (expense), net:
Interest expense, net (328) (565) (2,003) (1,635)
Other (expense) income, net (2) 16 (10) 40
Change in fair value of warrant liability 71 (80) (13) (3,581)
Change in fair value of derivative liability — — — 101
Change in fair value of earnout liability 2,410 (2,230) 2,210 (2,070)
Loss on issuance of debt — — — (6,640)
Loss on debt extinguishment and modification — (46) (8,294) (2,170)
Total non-operating income (expense), net 2,151 (2,905) (8,110) (15,955)
Loss before income tax expense (297) (4,557) (14,771) (19,692)
Income tax expense — — 2 3
Net loss and comprehensive loss (297) (4,557) (14,773) (19,695)
Net loss attributable to common stockholders (297) (4,557) (14,773) (19,695)
Net loss per share basic and diluted (0.02) (0.47) (0.99) (2.09)
Weighted-average shares outstanding 15,895 9,602 14,849 9,415

Condensed Consolidated Balance Sheets (Unaudited)

(In thousands, except per share data)

Description September 30, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents 8,124 10,412
Restricted cash and cash equivalents 300 50
Accounts receivable 7,344 5,781
Inventory 11,483 5,027
Prepaid expenses and other current assets 954 821
Total current assets 28,205 22,091
Property and equipment, net 889 318
Operating lease right-of-use assets, net 1,386 573
Other assets 39 39
Total assets 30,519 23,021
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable 3,681 3,580
Accrued expenses and other current liabilities 5,939 3,825
Current maturities of long-term debt — 9
Operating lease liabilities, current 541 454
Total current liabilities 10,161 7,868
Long-term debt, less current maturities, net 11,397 683
Related party notes payable 3,895 3,895
Operating lease liabilities 906 203
Warrant liability 116 103
Earnout liability — 2,210
Other liabilities 1,395 1,614
Total liabilities 27,870 16,576
Commitments and contingencies (Notes 6 and 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding — —
Common stock, $0.0001 par value; 500,000 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 14,671 and 11,902 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively 1 1
Additional paid-in capital 70,445 59,468
Accumulated deficit (67,797) (53,024)
Total stockholders’ equity 2,649 6,445
Total liabilities and stockholders’ equity 30,519 23,021

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In thousands)

Description Nine months ended September 30, 2026 Nine months ended September 30, 2025
Cash flows from operating activities:
Net loss (14,773) (19,695)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 96 115
Stock-based compensation 1,780 519
Loss on issuance of debt — 6,640
Loss on debt extinguishment and modification 8,294 2,170
Non-cash interest 1,123 749
Non-cash operating lease and other (13) (31)
Change in fair value of warrant liability 13 3,581
Change in fair value of derivative liability — (101)
Change in fair value of earnout liability (2,210) 2,070
Changes in operating assets and liabilities:
Accounts receivable (1,573) (3,177)
Inventory (6,781) (2,102)
Prepaid expenses and other current assets (132) (298)
Accounts payable 318 1,072
Accrued expenses and other current liabilities 2,102 1,831
Other liabilities 1,078 799
Net cash used in operating activities (10,678) (5,858)
Cash flows from investing activities:
Purchases of property and equipment (263) (47)
Net cash used in investing activities (263) (47)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants, net of issuance costs 9,045 679
Proceeds from long-term debt, net of issuance costs — 15,000
Proceeds from stock option exercises 246 75
Proceeds from warrant exercises — 532
Repayment of long-term debt (9) (4,688)
Payments for taxes related to net settlement of equity awards (94) —
Payment of stock issuance costs (285) —
Payment of debt issuance costs — (150)
Repurchase of warrant from Yorkville — (5,000)
Net cash provided by financing activities 8,903 6,448
Net (decrease) increase in cash and cash equivalents and restricted cash and cash equivalents (2,038) 543
Cash and cash equivalents and restricted cash and cash equivalents, beginning balance 10,462 1,192
Cash and cash equivalents and restricted cash and cash equivalents, ending balance 8,424 1,735
Reconciliation of cash and cash equivalents and restricted cash and cash equivalents to the condensed consolidated balance sheets:
Cash and cash equivalents 8,124 1,715
Restricted cash and cash equivalents 300 20
Total cash and cash equivalents and restricted cash and cash equivalents 8,424 1,735
Supplemental disclosure of cash flow information:
Cash paid for income taxes 2 —
Cash paid for interest — 12
Supplemental disclosures of noncash investing and financing activities:
Transfer of inventory to property and equipment 325 —
Lease liabilities from obtaining right-of-use asset 1,132 —
Accrued interest capitalized upon debt extinguishment 1,297 —

Amounts as printed on the EDGAR/iXBRL face — (In thousands, except per share data); (In thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗